UBS lowered the firm’s price target on UiPath (PATH) to $13 from $17 and keeps a Neutral rating on the shares. UiPath reported Q4 results in line with expectations and guided to FY27 revenue growth of 9% and annual recurring revenue growth of 11%, slightly above investor targets, though constant-currency net new ARR has yet to return to growth, the analyst tells investors in a research note. While AI tailwinds may support automation demand, organic net new ARR appears roughly flat year over year, leaving the risk/reward balanced, UBS says.
Claim 55% Off TipRanks
Trade PATH with leveragePublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PATH:
- UiPath Delivers First Full-Year Profit and New Buyback
- Closing Bell Movers: Netscope down 17%, UiPath down 5% on earnings
- UiPath raises long-term operating margin target to 30% from above 20%
- PATH Earnings: UiPath’s Financial Results Top Wall Street Forecasts
- UiPath reports Q4 adjusted EPS 30c, consensus 25c